Encouragement to pharmaceutical companies to register medicines commonly used in Named Patient Programmes

List of the most commonly used NPP medicines in April.

15.5.2020

The Icelandic Medicines Agency (IMA) hereby publishes a list of the most commonly prescribed medicinal products in Named Patient Programmes (NPPs) in April 2020. The list only includes approved prescriptions.

The purpose of publishing this information is to encourage pharmaceutical companies to apply for marketing authorisations and market the products listed, or comparable medicines. The advantage of having a medicinal product authorised and marketed, is that NPP prescriptions are usually not approved by IMA if a comparable medicinal product with an MA is marketed. It is therefore beneficial for all parties involved to have proper registration for the medicinal products that are sold in Iceland. Benefits for users include updated information in Icelandic, for both healthcare professionals and patients.

Most of the medicinal products listed below are absent from the market, whereas a few of them (starred) are temporary substitutions for registered medicinal products.

This list only includes medicinal products used in NPPs prescribed to individuals, but neither includes unregistered medicines used at hospitals and health institutions, nor medicines prescribed by veterinarians.

 *Medicinal productATC code Number of approved
prescriptions in April  
 Doloproct suppositoriesC05AA08 655
 Xyloproct suppositories C05AA01 339
 Senokot A06AB06 161
 *Nifurantin J01XE01139
 BromamN05BA08 117
 *Uro-Tablinen J01XE01  114
 Co-TrimoxazoleJ01EE01 102
 *Nozinan N05AA02 99
 *Levomepromazine Orion N05AA02 97
 * Naprosyn entero M01AE02 84
 *Duac once daily D10AF5177
 SEM mixture R05DA20 74
 Quinine SulfateP01BC01 68
 Rohypnol N05CD03 65
 Miralax A06AD 46
 Methopromazine N05AA02  43
 Phenhydan N03AB02  39
 Glycerol Infant A06AX01  36
 Largactil N05AA01  35
 *Naproxen M01AE02 35 

Back Send article